drugset
drugset / Trial / NCT07130604

Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis

NCT07130604 ↗

Phase 3 Recruiting 390 enrolled InventisBio Co., Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis.

Timeline

Start
2025-09-18
Primary completion
2027-07-28
Completion
2027-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject D-2570 Unknown — —

Indications

psoriasis